title: Rolapitant: a pooled analysis of its efficacy and safety in the prophylaxis of chemotherapy-induced nausea and vomiting.
abstract: BACKGROUND
  We conducted a pooled analysis of rolapitant-containing regimens versus control in the prophylaxis of chemotherapy-induced nausea and vomiting.
  
  
  METHODS
  Eligible studies included randomized studies evaluating rolapitant-containing regimens in the settings of highly emetogenic and moderately emetogenic chemotherapy.
  
  
  RESULTS
  The pooled relative risk for complete response in the overall phase was 1.23 (95% CI: 1.18-1.33; p < 0.00001), the pooled relative risk for no significant nausea in the overall phase was 1.17 (95% CI: 1.04-1.32; p = 0.008) and the pooled RR for no emesis in the overall phase was 1.24 (95% CI: 1.18-1.31; p < 0.00001).
  
  
  CONCLUSIONS
  Rolapitant-based regimens are associated with higher rates of complete response, no significant nausea and no emesis with highly/moderately emetogenic chemotherapy compared with control regimens.
authors.affiliation: Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
authors.forename: Omar
authors.initials: O
authors.lastname: Abdel-Rahman
authors.affiliation: Medical Microbiology & Immunology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
authors.forename: Mona
authors.initials: M
authors.lastname: Fouad
mesh_terms: D000932:Antiemetics / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009325:Nausea / Q000188:drug therapy* / Q000209:etiology*; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy; D016017:Odds Ratio; D011292:Premedication; D017594:Publication Bias; D016032:Randomized Controlled Trials as Topic; D013141:Spiro Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014839:Vomiting / Q000188:drug therapy* / Q000209:etiology*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D013141:Spiro Compounds; C578834:rolapitant
keywords: chemotherapy; nausea; rolapitant; vomiting